E2 conjugating inhibitors are a class of compounds that target ubiquitin-conjugating enzymes (E2 enzymes) in the ubiquitin-proteasome system. These enzymes play a crucial role in transferring ubiquitin molecules to target proteins, marking them for degradation. By inhibiting E2 conjugating enzymes, these compounds disrupt the ubiquitination process, potentially leading to the stabilization of specific proteins. This targeted intervention has applications in various research areas, including cancer therapy, where controlling protein degradation can be a valuable strategy. The development of E2 conjugating inhibitors is an active area of research in the field of drug discovery and proteasome biology.
